Meeting Report: Exploiting the Tumor Microenvironment for Therapeutics
Open Access
- 1 May 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (9), 4558-4560
- https://doi.org/10.1158/0008-5472.can-06-0069
Abstract
Recent progress in understanding the role of the tumor microenvironment in cancer progression was the subject of the 2nd International Tumor Metabolism Summit entitled “Exploiting the Tumor Microenvironment for Therapeutics,” a meeting held at Palazzo Ducale in Genoa, Italy, October 7 to 8, 2005. One of the major conceptual advances in oncology over the last decade has been the appreciation that all major aspects of cancer biology are influenced by the tumor microenvironment. Two important means by which cancer cells adapt to their microenvironment are by reprogramming cellular glucose/energy metabolism to use pathways that generate ATP in the absence of O2 and by stimulating angiogenesis to increase O2 delivery. These responses are principally mediated at the transcriptional level by hypoxia-inducible factor-1. This meeting emphasized the complexity of the tumor microenvironment and opportunities for therapeutic intervention by targeting transcriptional and metabolic pathways that are activated during cancer progression. A better understanding of the crosstalk between signaling pathways and metabolic alterations that contribute to the cancer phenotype may provide insights leading to the development of novel therapeutic strategies. (Cancer Res 2006; 66(9): 4558-60)Keywords
This publication has 10 references indexed in Scilit:
- Hypoxia-Inducible Factor-1-Dependent Repression of E-cadherin in von Hippel-Lindau Tumor Suppressor–Null Renal Cell Carcinoma Mediated by TCF3, ZFHX1A, and ZFHX1BCancer Research, 2006
- Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding ActivityCancer Research, 2005
- Involvement of PI3K and MAPK Signaling in bcl-2-induced Vascular Endothelial Growth Factor Expression in Melanoma CellsMolecular Biology of the Cell, 2005
- Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its ReceptorCancer Research, 2005
- HIF-1α expression regulates the bactericidal capacity of phagocytesJournal of Clinical Investigation, 2005
- The MET oncogene drives a genetic programme linking cancer to haemostasisNature, 2005
- Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma XenograftsCancer Research, 2004
- A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesisCarcinogenesis: Integrative Cancer Research, 2004
- Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy TargetCell Cycle, 2004
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003